Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

NCT02258555 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: GS-9901

Sponsor

Gilead Sciences